By contrast, the preponderance of GBM patients (60%) harbor unmethylated MGMT and exhibit chemoresistance to TMZ [1–3, 5–12], markedly reducing survival (PFS = 5.3 months, OS = 12.7 months) [2]. The gene discussed is MGMT; the disease is glioblastoma.